Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-associated mortality worldwide with an overall five-year survival rate less than 7%. Accumulating evidence has revealed the cancer preventive and therapeutic effects of metformin, one of the most widely prescri...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer
Main Authors: Chen, Ke, Qian, Weikun, Jiang, Zhengdong, Cheng, Liang, Li, Jie, Sun, Liankang, Zhou, Cancan, Gao, Luping, Lei, Meng, Yan, Bin, Cao, Junyu, Duan, Wanxing, Ma, Qingyong
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5525317/
https://ncbi.nlm.nih.gov/pubmed/28738823
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-017-0701-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados